|

GPRC5D/CD3 BiTEs Clinical Trials

3 actively recruiting trials

Pipeline

Phase 2: 3

Top Sponsors

  • Institute of Hematology & Blood Diseases Hospital, China3

Indications

  • Cancer3
  • Multiple Myeloma, Newly Diagnosed2
  • Multiple Myeloma, Plasma Cell Leukemia1

Other3 trials

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
Phase 2
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Phase 2
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.